Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06183307 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effects of Nattokinase on Inflammation and Cardiovascular Risk Markers in Patients With Dyslipidemia

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Dec 20, 2025 to Dec 20, 2026
    • Study completion date: Jul 31, 2026 to Dec 20, 2026
    • Site details revised
    v5
  2. Trial status: Not Yet Recruiting to Recruitingv4 Show 5 more changesShow less
    • Primary completion date: Dec 20, 2024 to Dec 20, 2025
    • Study sites: 0 to 1
    • Study completion date: Jul 31, 2025 to Jul 31, 2026
    • Start date changed from estimate of Jun 3, 2024 to Aug 3, 2024
    • Collaborators reordered
  3. Start date: Mar 1, 2024 to Jun 3, 2024v3
  4. Primary endpoint revised
    • Eligibility criteria shortened, about 32 words
    • Secondary endpoint revised
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study aims to evaluate the effect of the nattokinase enzyme on inflammation and markers of cardiovascular risk in participants with dyslipidemia. A longitudinal double-blind randomized clinical trial will be carried out, involving hypertensive participants with dyslipidemia for two months.
Trial Details
NCT Number NCT06183307
Lead Sponsor Universidade Federal Fluminense
Collaborators: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior., Rio de Janeiro State Research Supporting Foundation (FAPERJ)
Conditions
(from sponsor)		 Cardiovascular Diseases, Dyslipidemias, Inflammation
Related terms Cardiovascular Diseases, Dyslipidemias, Inflammation
Enrollment 48 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov